SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing heavy selling pressure as investors scrutinize the company's aggressive debt-funded AI infrastructure expansion and potential concentration risk related to OpenAI. While the community remains divided between those viewing the steep price decline as a capitulation-driven buying opportunity and others concerned about long-term management strategy and capital allocation, sentiment is heavily influenced by intense algorithmic volatility.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is trending as the community debates whether the stock is a long-term play on financial infrastructure or a victim of increasing competition from traditional payment giants like Visa and Mastercard. While bullish investors point to potential breakthroughs from the Clarity Act and institutional adoption, others are actively trading based on significant volatility and technical gap-fill levels.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is gaining significant momentum as investors digest recent leadership additions and anticipate the official initiation of the global Phase 3 AURORA trial for non-small cell lung cancer. Community sentiment remains highly bullish, with active discussions focusing on the company's potential to disrupt the oncology market, the strategic value of its immune-activating platform, and the possibility of future acquisition by major pharmaceutical players.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending as investors rotate into clean energy infrastructure following a strategic 380MW data center power deal that signals a shift from project proposals to active commercial execution. The community is actively debating the company's valuation gap compared to peers, while monitoring management's ability to convert pipeline demand into binding backlog and sustainable revenue.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is experiencing significant volatility and trading momentum driven by a strong re-rating as investors pivot the stock toward an AI data center power infrastructure narrative. While the community is actively debating the sustainability of these gains versus potential short-squeeze dynamics, bullish sentiment is being further fueled by recent insider buying from the CEO and speculative interest in the company's new solid-state transformer technology.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is seeing intense community debate driven by its recent inclusion in the Russell 3000 index and ongoing speculation surrounding potential defense-sector supercycles and counter-drone contract opportunities. While bulls are focused on the company's autonomous systems partnerships and backlog growth, the stock is experiencing significant volatility as market participants clash over the impact of recent share dilution and heavy short interest.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to significant institutional accumulation and speculation surrounding its obesity pipeline, particularly as the market monitors upcoming Q3 maintenance study data. Community discussion is heavily focused on potential M&A activity, with long-term holders debating the likelihood of a buyout as the company progresses its VK2735 and VK3019 programs against sector heavyweights.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is trending following a significant earnings beat and record backlog growth, which investors are weighing against soft forward guidance and margin concerns. The community is actively debating the stock's long-term potential in the defense drone super-cycle, with bullish sentiment focused on autonomous warfare demand while bears point to valuation risks and recent share price volatility.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is trending due to significant momentum in the 'Physical AI' sector, fueled by its new strategic manufacturing agreement for its REV8 sensor family and recent high-profile infrastructure deployments ahead of the 2026 World Cup. Community sentiment is largely focused on the company's critical role as an enabler for robotics and autonomous systems, with many investors debating whether current price action represents a sustainable breakout for long-term compounding or a high-volatility momentum play.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is currently experiencing intense downward pressure as investors react to management's cautious commentary on its Watchman growth outlook, leading to a significant breakdown in price. The community is actively debating whether this represents a long-term value opportunity bolstered by ongoing share repurchases or a sign of deeper structural issues, with many traders looking for a capitulation point to enter a relief bounce.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Spyglass Pharma, Inc. (NASDAQ:SGP) Receives Average Rating of "Moderate Buy" from Analysts

Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six analysts that are presently covering the company, Marketbeat reports. One...

Spyglass Pharma (NASDAQ:SGP) Stock Price Up 8.6% - Here's What Happened

Spyglass Pharma (NASDAQ:SGP) Shares Up 8.6% - Here's Why...

Spyglass Pharma (NASDAQ:SGP) Hits New 1-Year Low - What's Next?

Spyglass Pharma (NASDAQ:SGP) Hits New 12-Month Low - Here's Why...

Spyglass Pharma (NASDAQ:SGP) Trading Down 5.2%  - Here's Why

Spyglass Pharma (NASDAQ:SGP) Stock Price Down 5.2% - Time to Sell...

HC Wainwright Lifts Earnings Estimates for Spyglass Pharma

Spyglass Pharma, Inc. (NASDAQ:SGP - Free Report) - Analysts at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for Spyglass Pharma in a report issued on Monday, March 30th...

Spyglass Pharma, Inc. (NASDAQ:SGP) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have issued a...

Spyglass Pharma (NASDAQ:SGP) Cut to "Sell" at Wall Street Zen

Wall Street Zen cut Spyglass Pharma from a "hold" rating to a "sell" rating in a research note on Saturday...

Spyglass Pharma (NASDAQ:SGP) Releases Earnings Results, Beats Expectations By $0.89 EPS

Spyglass Pharma (NASDAQ:SGP - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($5.72) earnings per share (EPS) for the quarter, topping analysts' consensus...

Spyglass Pharma (NASDAQ:SGP) Stock Price Up 8.7% - Time to Buy?

Spyglass Pharma (NASDAQ:SGP) Stock Price Up 8.7% - Should You Buy...

Spyglass Pharma (NASDAQ:SGP) Stock Price Down 10.1% - Time to Sell?

Spyglass Pharma (NASDAQ:SGP) Shares Down 10.1% - Here's Why...

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.

SpyGlass Pharma Inc.

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

SGPSpyGlass Pharma Inc.

Latest SGP News